WallStSmart

Amrize Ltd (AMRZ)vsCemex SAB de CV ADR (CX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Cemex SAB de CV ADR generates 43% more annual revenue ($17.04B vs $11.91B). AMRZ leads profitability with a 9.7% profit margin vs 2.8%. CX appears more attractively valued with a PEG of 0.11. CX earns a higher WallStSmart Score of 56/100 (C).

AMRZ

Hold

49

out of 100

Grade: D+

Growth: 4.0Profit: 5.0Value: 5.7Quality: 5.0
Piotroski: 2/9Altman Z: 1.61

CX

Buy

56

out of 100

Grade: C

Growth: 4.7Profit: 5.0Value: 7.0Quality: 5.5
Piotroski: 4/9Altman Z: 1.48
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for AMRZ.

CXUndervalued (+12.3%)

Margin of Safety

+12.3%

Fair Value

$13.47

Current Price

$11.33

$2.14 discount

UndervaluedFair: $13.47Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AMRZ1 strengths · Avg: 8.0/10
Price/BookValuation
2.0x8/10

Reasonable price relative to book value

CX3 strengths · Avg: 10.0/10
PEG RatioValuation
0.1110/10

Growing faster than its price suggests

Price/BookValuation
1.3x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.0810/10

Conservative balance sheet, low leverage

Areas to Watch

AMRZ4 concerns · Avg: 3.8/10
Revenue GrowthGrowth
4.7%4/10

4.7% revenue growth

EPS GrowthGrowth
3.6%4/10

3.6% earnings growth

Altman Z-ScoreHealth
1.614/10

Distress zone — elevated risk

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

CX4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Return on EquityProfitability
3.9%3/10

ROE of 3.9% — below average capital efficiency

Profit MarginProfitability
2.8%3/10

2.8% margin — thin

Altman Z-ScoreHealth
1.482/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : AMRZ

The strongest argument for AMRZ centers on Price/Book. PEG of 1.37 suggests the stock is reasonably priced for its growth.

Bull Case : CX

The strongest argument for CX centers on PEG Ratio, Price/Book, Debt/Equity. Revenue growth of 12.2% demonstrates continued momentum. PEG of 0.11 suggests the stock is reasonably priced for its growth.

Bear Case : AMRZ

The primary concerns for AMRZ are Revenue Growth, EPS Growth, Altman Z-Score.

Bear Case : CX

The primary concerns for CX are EPS Growth, Return on Equity, Profit Margin. Thin 2.8% margins leave little buffer for downturns.

Key Dynamics to Monitor

CX is growing revenue faster at 12.2% — sustainability is the question.

Monitor BUILDING MATERIALS industry trends, competitive dynamics, and regulatory changes.

Bottom Line

CX scores higher overall (56/100 vs 49/100) and 12.2% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Amrize Ltd

BASIC MATERIALS · BUILDING MATERIALS · USA

Amrize Ltd (AMRZ) is an innovative technology firm at the forefront of the digital health and wellness industry, dedicated to transforming healthcare delivery with cutting-edge technologies and data-driven solutions. The company prioritizes enhancing patient outcomes and access to care, significantly investing in research and development to address the rising demand for scalable health innovations. With a diverse portfolio of products and strategic initiatives, Amrize is well-positioned to become a critical player in the ongoing evolution of healthcare, presenting a compelling investment opportunity for institutional investors navigating a dynamic market.

Visit Website →

Cemex SAB de CV ADR

BASIC MATERIALS · BUILDING MATERIALS · USA

CEMEX, SAB de CV, produces, markets, distributes and sells cement, ready-mix concrete, aggregates, clinker and other construction materials worldwide. The company is headquartered in San Pedro Garza Garca, Mexico.

Want to dig deeper into these stocks?